Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Journal of Medicinal Chemistry

Discovery of Novel Potent Triple IKZF1/2/3 Degraders for the Treatment of Hematological Cancers

View Full Paper
Ask AI
Bookmark
Share

Authors

TWTing WeiQingdao UniversitySSShiyang SunCenter for Strategic ResearchXHXiaotong HuArmy Medical University

Discussion

Loading...

Member takes

Overview

Screening reveals MGD-22 effectively overcomes pomalidomide resistance in hematological cancers, suggesting novel therapeutic pathways.

Key Points

  • MGD-22 showed significant tumor growth inhibition in multiple myeloma and leukemia models, indicating potential efficacy.
  • The compound exhibited nanomolar-range IC50 potency against various cancer cells, proving its effectiveness across diverse targets.
  • By inducing degradation of IKZF1/2/3 via the Cullin-CRBN pathway, MGD-22 presents a novel approach to overcoming drug resistance.
  • The study highlights MGD-22's favorable pharmacokinetic profile and synergistic effects with other inhibitors in DLBCL cells.

Cite This Study

Wei et al. (2025) studied this question.

synapsesocial.com/papers/68c23dc5b210217d6478f4dahttps://doi.org/10.1021/acs.jmedchem.5c01086
View Full Paper
Ask AI
Bookmark
Share